1.Novel agents for multiple myeloma bone disease
Journal of Leukemia & Lymphoma 2014;23(2):123-127
Bone disease is a major morbidity factor in patients with multiple myeloma and significantly affects their overall survival.A complex interplay between malignant plasma cells and other marrow cells results in the generation of a microenvironment to enhance both tumor growth and bone destruction.Bisphosphonates have consistently reduced the incidence of skeletal-related events in patients with multiple myeloma.However,their use is burdened with side-effects,including the risks of osteonecrosis of the jaw and kidney failure,suggesting that they should be discontinued after prolonged administration.New molecular targets of cell cross-talk in myeloma bone marrow are therefore under intensive investigation and new drugs are exploring in preclinical and clinical studies of myeloma bone disease.This review would focus on novel agents in myeloma bone disease.
2.Bruton tyrosine kinase inhibitor in B cell malignancies
Guangzhong YANG ; Chuanying GENG
Journal of Leukemia & Lymphoma 2013;22(8):504-506
Bruton tyrosine kinase (BTK) is a non-receptor tyrosine kinase which belongs to the Tec kinase family and plays an important role in B cell receptor signaling.Nowadays,BTK has been a nove] target for treating some B cell malignancies.Recently,some studies have confirmed that BTK inhibitor,PCI-32765 (ibrutinib),can effectively treat chronic lymphocytic leukemia,mantle cell lymphoma and so on.This review will discuss the preclinical and clinical development of this BTK inhibitor in B cell malignancies.
3.Comparison of the stability of three internal fixators for distal femoral fracture
Kanghua YANG ; Jing YANG ; Guangzhong YANG
Chinese Journal of Tissue Engineering Research 2014;(4):565-570
BACKGROUND:There are various internal fixators in treatment of distal femoral fracture. The commonly used fixators are locking compression plate, anterograde intramedul ary nails and retrograde intramedul ary nails. However, the efficacy of three common fixation is controversial.
OBJECTIVE:To compare the effect of locking compression plate, anterograde intramedul ary nails and retrograde intramedul ary nails for treatment of distal femoral fracture, and to select the appropriate internal fixation method.
METHODS:From May 2007 to November 2007, 118 patients with distal femoral fractures were treated with internal fixation in the hospital and their clinical data were analyzed retrospectively. Among them, 38 cases received locking compression plate, 21 cases received anterograde intramedul ary nails, and 59 cases received retrograde intramedul ary nails. The intraoperative blood loss, operative time, fracture healing time and rate of good postoperative recovery of knee joint in three groups were compared.
RESULTS AND CONCLUSION:Al the involved 118 patients were fol owed up for 14-26 months, average 20 months. No patients developed infection. Except one case delayed bone defect healing due to the fractures and was completely healed after bone fil ing at 19 weeks, the other cases healed within 4.5 months. There was no significant difference in fracture healing time among three groups (P>0.05). Intraoperative blood loss and operation time in anterograde intramedul ary nail group and retrograde intramedul ary nail group were superior to locking compression plate group. In addition, anterograde intramedul ary nail group was superior to retrograde intramedul ary nail group, with significant difference (P<0.05). Kolment grading fine rate in locking compression plate, anterograde intramedul ary nail and retrograde intramedul ary nail groups was 76.3%, 52.4%and 76.3%respectively. Retrograde intramedul ary nail fixation is firm, stable and reliable, with less intraoperative blood loss, shorter operation time, smal trauma, and easy fracture reset, especial y in the recovery of knee joint function. Compared with locking compression plate and anterograde intramedul ary nail, retrograde intramedul ary nailing treatment of distal femoral fractures has more advantages.
4.Determination of ginsenoside Rg1 and ginsenoside Re in Wushenqi Oral Liquid by RP-HPLC
Guangzhong WANG ; Di HU ; Yang ZHOU
Chinese Traditional Patent Medicine 1992;0(04):-
AIM: To develop a RP-HPLC method of determining ginsenoside Rg1 and ginsenoside Re in Wu-(shenqi) Oral Liquid(Radix et Rhizoma Ginseng,Radix Astragali,Fructus Ligustri Lucidi,etc.). METHODS: Hypersil-C_(18) column was used at 30 ℃.The mobile phase consisted of acetonitrile-water(103∶400) with 0.05% H_3PO_4.The detection wavelength was set at 203 nm.The flow rate was 1.0 mL/min. RESULTS: The linear ranges for ginsenoside Rg1 and ginsenoside Re were 0.188-6.016 ?g(r=0.999 9) and 0.197-6.323 ?g(r=(0.999)),respectively.Its average recoveries were 99.53% with RSD of 0.96% and 99.13% with RSD of 0.62%,respectively. CONCLUSION: This method is simple,accurate,reproducible,and can be used for the determination of ginsenoside Rg1 and ginsenoside Re in Wushenqi Oral Liquid.
5.Chemical components of Piper hancei (Ⅰ)
Liang ZHOU ; Junshan YANG ; Guangzhong TU
Chinese Traditional and Herbal Drugs 1994;0(01):-
Objective To investigate the chemical constituents in the vines of Piper hancei for obtaining a more comprehensive understanding on its effective components. Methods Compounds were separated by column chromatography with silica gel and polyamide, and their structures were elucidated by spectral analysis and chemical evidence (IR, UV, MS, (~1H-NMR), (~(13)C-NMR)). Results Nine compounds were isolated from the chloroform extract fraction. Their structures were identified as: futoamide (Ⅰ), trichostachine (Ⅱ), retrofractamide A (Ⅲ), pipercide (Ⅳ), guineensine (Ⅴ), piperine (Ⅵ), piperettine (Ⅶ), piperovatine (Ⅷ), and (2E, 4E)-N-isobutyl-7-(3, 4-methylenedioxyphenyl)-hepta-2, 4-dienamide (Ⅸ). (Conclusion )Compounds Ⅱ-Ⅳ and Ⅶ-Ⅸ are isolated from the plant for the first time.
6.Effect of oleanolic acid derivatives on improving insulin resistance and its molecular mechanism
Jing XU ; Linhui ZHU ; Debin WANG ; Xin HU ; Guangzhong YANG
Chinese Pharmacological Bulletin 2014;(11):1585-1589
Aim To detect the effect of Bio on impro-ving insulin resistance and explore its molecular mech-anism. Methods The HepG2 liver cells were derivat-ed by high concentration insulin to establish the insulin resistance cell model, and the cells were intervened by Bio. The glucose consumption was measured by glu-cose oxidase and peroxidase ( GOD-POD) assay. The expression of PPARγmRNA was detected by RT-PCR. The expression of PPARγ protein was detected by Western blot method. Results The glucose consump-tion was significantly decreased in the insulin resist-ance cells after incubated with 1 . 72 × 10 -5 mol · L-1 insulin ( P<0. 05 ) . 10 -5 ,10 -6 ,10 -7 mol · L-1 Bio increased the glucose consumption 135%,62%,39%separately in the insulin resistance cells. RT-PCR a-nalysis of PPARγ showed that Bio raised the PPARγmRNA. Western blot analysis displayed that the pro-tein of PPARγ with Bio was increased. Conclusion Bio can improve the insulin resistance of the HepG2 cells, and the molecular mechanism may be relevant with raising PPARγ expression.
7.Locking plate combined with anti-osteoporosis drugs for osteoporotic proximal humerus fractures in elderly patients
Diqing ZHAO ; Chuang MA ; Guangzhong YANG ; Keyi CHEN ; Ruping LIU
Journal of Medical Postgraduates 2014;(6):619-622
Objective Proximal humerus fracture is the most common upper-arm osteoporotic fracture in elderly patients and the result of treatment directly affects the physiological function of the shoulder .This article discusses the clinical effect of the locking proximal humeral plate ( LPHP) combined with anti-osteoporosis drugs in the treatment of osteoporotic comminuted proximal humerus fractures in elderly patients . Methods This study included of 47 elderly osteoporotic patients with comminuted proximal humerus fractures treated from April 2009 to March 2012 and with complete follow-up data.According to the Neer classification , the patients were divided into groups A (LPHP treatment, n=23, including 13 cases of three-part fractures and 10 cases of four-part fractures) and B (LPHP+anti-osteoporosis drugs, n=24, including 13 cases of three-part fractures and 11 cases of four-part fractures). Results All the patients were followed up for 14 to 38 (mean 23.6) months.The postoperative healing time was significantly shorter in group B than in group A ([96.57 ±2.59]d vs [115.91 ±2.73]d, P<0.05), and the excellence rate was remarkably higher in B than in A (91.7%vs 78.3%,P<0.05). Conclusion With the advantages of short healing time and high excellence rate , LPHP+anti-os-teoporosis drugs is superior to simple LPHP in the treatment of osteoporotic comminuted proximal humerus fractures in elderly patients.
8.Synthesis and photochemical virus inactivation of novel phenothiazines.
Hui WEN ; Xiaofang WANG ; Yi HUANG ; Jingxing WANG ; Guangzhong YANG
Acta Pharmaceutica Sinica 2010;45(1):72-6
Virus inactivation with photochemistry is being suitable for blood or blood products, methylene blue (MB)/light treatment has been used for viral inactivation of cellular blood components. Twelve new phenothiazines derivatives were designed and synthesized, and were used to test viral inactivation and red cell damage preliminary. Results showed that compound YWW-7 has a satisfactory activity, it could be developed as a new viral inactivation agent for blood products.
9.Sulfur-containing amides from Entada phaseoloides.
Hui XIONG ; Er XIAO ; Yinghong ZHAO ; Guangzhong YANG ; Zhinan MEI
Acta Pharmaceutica Sinica 2010;45(5):624-6
To study the chemical constituents of the Entada phaseoloides (L.) Merr., seeds of Entada phaseoloides were extracted with 70% ethanol at room temperature. Isolation and purification were performed by silica gel, reversed-phase silica gel column chromatography and semi-preparative HPLC. Structures of the pure compounds were established on the basis of spectral analysis. Four sulfur-containing amide compounds were isolated from the n-BuOH-soluble fraction and identified as entadamide A-beta-D-glucopyranosyl-(1-->3)-beta-D-glucopyranoside (1), entadamide A (2), entadamide A-beta-D-glucopyranoside (3) and clinacoside C (4). Compound 1 is a new compound. Compound 4 is isolated from the genus Entada for the first time.
10.A new chromone derivative from Berchemia lineata.
Yuxia SHEN ; Hongli TENG ; Guangzhong YANG ; Zhinan MEI ; Xiaolong CHEN
Acta Pharmaceutica Sinica 2010;45(9):1139-43
To study the chemical constituents from the root of Berchemia lineata (L.) DC., nine compounds were isolated from the EtOAc extract by using silica gel, RP-C18 silica gel column chromatography and preparative HPLC. Based on the spectroscopic analysis, their structures were identified as 5-hydroxy-7-(2'-hydroxypropyl)-2-methyl-chromone (1), (-)-(1'R, 2'S)-erythro-5-hydroxy-7-(1', 2'-dihydroxypropyl)-2-methyl-chromone (2), naringenin (3), eriodictyol (4), (+)-aromadendrin (5), (+)-taxifolin (6), (+)-catechin (7), (+)-epigallocatechin (8) and quercetin (9). Among them, compound 2 is a new chromone derivative. Compound 1 is a known chromone derivative and isolated from this genus for the first time. Compounds 3-9 are known flavonoids and isolated from this plant for the first time.